REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Back to transformations
BeforeBefore
AfterAfter
by Eden Volkov 541 · 20 days ago

12-week BPC-157 and TB-500 recovery protocol. Started with significant joint pain and limited mobility. By week 8, I was back to full training.

BPC-157TB-500
2025-08-23 → 2026-03-1128 weeks

Comments (2)

Taylor Nguyen 152·4 days ago

The before and after difference is noticeable. Did you experience any side effects during the protocol?

Taylor Novak 852·4 days ago

Thanks for being transparent about the timeline. Too many people exaggerate how quickly results come.

Sign in to comment.